VTRS

Here's Why Viatris (VTRS) is a Strong Value Stock

ISCV Beat IJJ Over the Past Year. Here's Why That Gap Could Easily Reverse.

GLP-1 Drugs Powered IHE's Big Year. IXJ Is Playing a Longer Game.

FDA Accepts Viatris' NDA for Fast-Acting Non-Opioid Pain Therapy

Here's Why Viatris (VTRS) is a Strong Momentum Stock

U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain